Blueprint Medicines Corp
NASDAQ:BPMC

Watchlist Manager
Blueprint Medicines Corp Logo
Blueprint Medicines Corp
NASDAQ:BPMC
Watchlist
Price: 97.84 USD 0.99%
Market Cap: 6.2B USD
Have any thoughts about
Blueprint Medicines Corp?
Write Note

Relative Value

The Relative Value of one BPMC stock under the Base Case scenario is 167.84 USD. Compared to the current market price of 97.84 USD, Blueprint Medicines Corp is Undervalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BPMC Relative Value
Base Case
167.84 USD
Undervaluation 42%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
58
vs Industry
28
Median 3Y
16.8
Median 5Y
16.8
Industry
8.1
Forward
11.9
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-6.9
Industry
23
Forward
-96.9
vs History
vs Industry
Median 3Y
-11.4
Median 5Y
-10.1
Industry
23.4
vs History
vs Industry
Median 3Y
-12
Median 5Y
-10.7
Industry
27.3
vs History
9
vs Industry
3
Median 3Y
7.5
Median 5Y
5.9
Industry
2.6
vs History
52
vs Industry
25
Median 3Y
14.5
Median 5Y
14.5
Industry
8.1
Forward
11
vs History
46
vs Industry
22
Median 3Y
15.4
Median 5Y
12.8
Industry
9.6
vs History
vs Industry
Median 3Y
-6.3
Median 5Y
-6.1
Industry
4.3
Forward
-26.5
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.1
Industry
3.8
Forward
-25
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-8.1
Industry
6
vs History
vs Industry
Median 3Y
-9.7
Median 5Y
-7.9
Industry
3.8
vs History
12
vs Industry
15
Median 3Y
7.6
Median 5Y
7.6
Industry
4.8

Multiples Across Competitors

BPMC Competitors Multiples
Blueprint Medicines Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Blueprint Medicines Corp
NASDAQ:BPMC
6.2B USD 14.2 -48.3 -21.8 -20.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.9 37.4 17.5 33.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 11.9 -263.9 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 4.1 910.1 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 6.3 18.8 17.3 19.2
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
US
Blueprint Medicines Corp
NASDAQ:BPMC
Average P/E: 211.8
Negative Multiple: -48.3
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.1
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Blueprint Medicines Corp
NASDAQ:BPMC
Average EV/EBITDA: 17.9
Negative Multiple: -21.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
US
Blueprint Medicines Corp
NASDAQ:BPMC
Average EV/EBIT: 23.2
Negative Multiple: -20.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top